Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial

被引:222
作者
Derman, Richard J.
Kodkany, Bhalchandra S.
Goudar, Shivaprasad S.
Geller, Stacie E.
Naik, Vijaya A.
Bellad, M. B.
Patted, Shobhana S.
Patel, Ashlesha
Edlavitch, Stanley A.
Hartwell, Tyler
Chakraborty, Hrishikesh
Moss, Nancy
机构
[1] Univ Illinois, Coll Med, Dept Obstet & Gynecol MC 808, Chicago, IL 60612 USA
[2] Univ Missouri, Sch Med, Kansas City, MO 64108 USA
[3] Jawaharlal Nehru Med Coll, Belgaum, Karnataka, India
[4] John H Stroger Jr Hosp Cook Cty, Chicago, IL USA
[5] RTI Int, Stat & Epidemiol, Res Triangle Pk, NC USA
[6] NICHHD, Bethesda, MD 20892 USA
关键词
D O I
10.1016/S0140-6736(06)69522-6
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Postpartum haemorrhage is a major cause of maternal mortality in the developing world. Although effective methods for prevention and treatment of such haemorrhage exist-such as the uterotonic drug oxytocin - most are not feasible in resource-poor settings where many births occur at home. We aimed to investigate whether oral misoprostol, a potential alternative to oxytocin, could prevent postpartum haemorrhage in a community home-birth setting. Methods In a placebo-controlled trial undertaken between September, 2002, and December, 2005, 1620 women in rural India were randomised to receive oral misoprostol (n=812) or placebo (n=808) after delivery. 25 auxiliary nurse midwives undertook the deliveries, administered the study drug, and measured blood loss. The primary outcome was the incidence of acute postpartum haemorrhage (defined as >= 500 mL bleeding) within 2 h of delivery. Analysis was by intention-to-treat. The trial was registered with the US clinical trials database (http://www.clinicaltrials.gov) as number NCT00097123. Findings Oral misoprostol was associated with a significant reduction in the rate of acute postpartum haemorrhage (12.0% to 6.4%, p < 0.0001; relative risk 0.53 [95% CI 0.39-0.74]) and acute severe postpartum haemorrhage (1.2% to 0.2%, p < 0.0001; 0.20 [0.04-0.91]. One case of postpartum haemorrhage was prevented for every 18 women treated. Misoprostol was also associated with a decrease in mean postpartum blood loss (262.3 mL to 214.3 mL, p < 0.0001). Postpartum haemorrhage rates fell over time in both groups but remained significantly higher in the placebo group. Women taking misoprostol. had a higher rate of transitory symptoms of chills and fever than the control. Interpretation Oral misoprostol was associated with significant decreases in the rate of acute postpartum haemorrhage and mean blood loss. The drug's low cost, ease of administration, stability, and a positive safety profile make it a good option in resource-poor settings.
引用
收藏
页码:1248 / 1253
页数:6
相关论文
共 41 条
  • [1] [Anonymous], JOURNAL OF OBSTETRIC
  • [2] Misoprostol for women's health: A review
    Blanchard, K
    Clark, S
    Winikoff, B
    Gaines, G
    Kabani, G
    Shannon, C
    [J]. OBSTETRICS AND GYNECOLOGY, 2002, 99 (02) : 316 - 332
  • [3] An analysis of anemia and pregnancy-related maternal mortality
    Brabin, BJ
    Hakimi, M
    Pelletier, D
    [J]. JOURNAL OF NUTRITION, 2001, 131 (02) : 604S - 614S
  • [4] Misoprostol for prevention of postpartum hemorrhage
    Bugalho, A
    Daniel, A
    Faúndes, A
    Cunha, M
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2001, 73 (01) : 1 - 6
  • [5] Oral misoprostol for the third stage of labor:: A randomized controlled trial
    Çaliskan, E
    Dilbaz, B
    Meydanli, MM
    Öztürk, N
    Narin, MA
    Haberal, A
    [J]. OBSTETRICS AND GYNECOLOGY, 2003, 101 (05) : 921 - 928
  • [6] Oral misoprostol for prevention of postpartum hemorrhage by paramedical workers in India
    Chandhiok, N
    Dhillon, BS
    Datey, S
    Mathur, A
    Saxena, NC
    [J]. INTERNATIONAL JOURNAL OF GYNECOLOGY & OBSTETRICS, 2006, 92 (02) : 170 - 175
  • [7] DALY SA, 1999, J AM OBSTET GYNE S1, V180, P68
  • [8] Misoprostol: a boon to safe motherhood ... or not?
    Darney, PD
    [J]. LANCET, 2001, 358 (9283) : 682 - 683
  • [9] Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors
    De Angelis, C
    Drazen, JM
    Frizelle, FA
    Haug, C
    Hoey, J
    Horton, R
    Kotzin, S
    Laine, C
    Marusic, A
    Overbeke, AJPM
    Schroeder, TV
    Sox, HC
    Van der Weyden, MB
    [J]. LANCET, 2005, 365 (9474) : 1827 - 1829
  • [10] The misoprostol third stage of labour study: a randomised controlled comparison between orally administered misoprostol and standard management
    El-Refaey, H
    Nooh, R
    O'Brien, P
    Abdalla, M
    Geary, M
    Walder, J
    Rodeck, C
    [J]. BRITISH JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2000, 107 (09): : 1104 - 1110